Is there justification for 4 cycles of consolidation therapy in AML?
The concept of postremission therapy in acute myeloid leukemia is quite old, dating back to a trial conducted in 1988 by the Cancer and Leukemia Group B. Yet even with more than 20 years of investigation into the optimal number of cycles for consolidation therapy, the answer is still not entirely cl...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
20 October 2016
|
| In: |
Best practice & research
Year: 2016, Volume: 29, Issue: 4, Pages: 341-344 |
| ISSN: | 1532-1924 |
| DOI: | 10.1016/j.beha.2016.10.008 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.1016/j.beha.2016.10.008 Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S1521692616300615 
|
| Author Notes: | Richard F. Schlenk |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1564154637 | ||
| 003 | DE-627 | ||
| 005 | 20230427142048.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 171006s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.beha.2016.10.008 |2 doi | |
| 035 | |a (DE-627)1564154637 | ||
| 035 | |a (DE-576)494154632 | ||
| 035 | |a (DE-599)BSZ494154632 | ||
| 035 | |a (OCoLC)1340980303 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Schlenk, Richard Friedrich |d 1965- |e VerfasserIn |0 (DE-588)129025380 |0 (DE-627)387778004 |0 (DE-576)297454102 |4 aut | |
| 245 | 1 | 0 | |a Is there justification for 4 cycles of consolidation therapy in AML? |c Richard F. Schlenk |
| 264 | 1 | |c 20 October 2016 | |
| 300 | |a 4 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 06.10.2017 | ||
| 520 | |a The concept of postremission therapy in acute myeloid leukemia is quite old, dating back to a trial conducted in 1988 by the Cancer and Leukemia Group B. Yet even with more than 20 years of investigation into the optimal number of cycles for consolidation therapy, the answer is still not entirely clear. Dose intensity also has an impact on the number of courses of consolidation therapy administered, as do the cytogenetics of the patients. This review examines how to direct the future of consolidation therapy outside of allogeneic transplantation and discusses the issues to consider in choosing the number of courses of consolidation, including the effect minimal residual disease may have in guiding decisions regarding consolidation treatment. | ||
| 650 | 4 | |a Acute myeloid leukemia | |
| 650 | 4 | |a AML | |
| 650 | 4 | |a CBF | |
| 650 | 4 | |a Consolidation | |
| 650 | 4 | |a Core binding factor | |
| 650 | 4 | |a Genetic landscape | |
| 650 | 4 | |a Minimal residual disease | |
| 650 | 4 | |a MRD | |
| 650 | 4 | |a Mutation status | |
| 650 | 4 | |a NPM1 | |
| 650 | 4 | |a Nucleophosmin 1 | |
| 773 | 0 | 8 | |i Enthalten in |t Best practice & research |d Amsterdam [u.a.] : Elsevier, 1999 |g 29(2016), 4, Seite 341-344 |h Online-Ressource |w (DE-627)32461442X |w (DE-600)2028865-7 |w (DE-576)105934569 |x 1532-1924 |7 nnas |a Is there justification for 4 cycles of consolidation therapy in AML? |
| 773 | 1 | 8 | |g volume:29 |g year:2016 |g number:4 |g pages:341-344 |g extent:4 |a Is there justification for 4 cycles of consolidation therapy in AML? |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.beha.2016.10.008 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S1521692616300615 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20171006 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 129025380 |a Schlenk, Richard Friedrich |m 129025380:Schlenk, Richard Friedrich |d 50000 |e 50000PS129025380 |k 0/50000/ |p 1 |x j |y j | ||
| 999 | |a KXP-PPN1564154637 |e 2982875896 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"extent":"4 S."}],"id":{"doi":["10.1016/j.beha.2016.10.008"],"eki":["1564154637"]},"title":[{"title_sort":"Is there justification for 4 cycles of consolidation therapy in AML?","title":"Is there justification for 4 cycles of consolidation therapy in AML?"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedKey":"2016","dateIssuedDisp":"20 October 2016"}],"relHost":[{"id":{"issn":["1532-1924"],"eki":["32461442X"],"zdb":["2028865-7"]},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Best practice & research","title":"Best practice & research"}],"origin":[{"publisherPlace":"Amsterdam [u.a.] ; London [u.a.]","dateIssuedKey":"1999","dateIssuedDisp":"1999-","publisher":"Elsevier ; Harcourt"}],"recId":"32461442X","disp":"Is there justification for 4 cycles of consolidation therapy in AML?Best practice & research","type":{"bibl":"periodical","media":"Online-Ressource"},"titleAlt":[{"title":"Best practice & research / Clinical haematology"},{"title":"Clinical haematology"},{"title":"Baillière's best practice & research / Clinical haematology"},{"title":"Baillière's best practice & research"}],"part":{"volume":"29","year":"2016","text":"29(2016), 4, Seite 341-344","issue":"4","extent":"4","pages":"341-344"},"language":["eng"],"note":["Gesehen am 07.01.20"],"pubHistory":["12.1999 -"]}],"name":{"displayForm":["Richard F. Schlenk"]},"language":["eng"],"note":["Gesehen am 06.10.2017"],"person":[{"role":"aut","family":"Schlenk","display":"Schlenk, Richard Friedrich","given":"Richard Friedrich"}],"recId":"1564154637"} | ||
| SRT | |a SCHLENKRICISTHEREJUS2020 | ||